All participants – Page 13 – Communicable Diseases Research

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

단회 투여 및 ChAdOx1 nCoV-19(AZD1222) 백신의 면역원성 및 효능에 대한 추가 투여 시간의 영향: 4건의 무작위 시험에 대한 통합 분석

Meta-Analysis

Published on 2021-03-062022-09-10
Journal: Lancet (London, England) [Category] MERS, SARS, 임상,

Absence of detection of RSV and influenza during the COVID-19 pandemic in a Brazilian cohort: Likely role of lower transmission in the community

브라질 코호트에서 COVID-19 범유행 기간 동안 RSV 및 인플루엔자 검출 부재: 지역사회에서 낮은 전염의 역할 가능성

Research Theme 1: COVID-19 Pandemic

Published on 2021-03-012022-09-10
Journal: Journal of Global Health [Category] SARS, 치료기술,

[키워드] Adults affected age All participants Brazil Care children cohorts Community contribute COVID-19 COVID-19 pandemic hospital Influenza influenza A influenza B knowledge measure median age other respiratory virus Other respiratory viruses participant Participants Pathogens pediatric Population positive prevalent Prospective Prospective Study reduce respiratory Respiratory pathogens respiratory syncytial virus respiratory viruses Result RSV RT-PCR test RT-PCR tests SARS-CoV-2 SARS-CoV-2 transmission seeking social distancing Spread Symptom therapeutic Transmission virus virus spread viruses was performed Winter
[DOI] 10.7189/jogh.11.05007 PMC 바로가기 [Article Type] Research Theme 1: COVID-19 Pandemic

Self-Perception of Changes in Routines in Adults and Older Adults Associated to Social Distancing Due to COVID-19—A Study in São Paulo, Brazil

Psychology

Published on 2021-02-232022-10-31
Journal: Frontiers in Psychology [Category] COVID-19,

Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations

코로나19 이후 합병증 및 신경학적 징후의 특성화 및 바이오마커 분석

Article

Published on 2021-02-132022-09-11
Journal: Cells [Category] MERS, 바이오마커, 진단,

[키워드] age All participants amyloid beta analyses antibody characterization co-morbidity collected Comorbidities Complication controls CoV COVID-19 COVID-19 infection cytokine Cytokines demonstrated dysfunction Exosome explain Extracellular had more IL-4 IL6 individual Infection initial Longitudinal studies longitudinal study manifestation marker MONITOR morbidity nCoV neurodegeneration neurogranin Neuroinflammation neurologic neurological neurological problem neurological problems Neurological symptom Neurological symptoms neuronal pandemic participant Participants plasma plasma biomarker Plasma cytokine positive correlation Protein Proteins recovering from COVID-19 SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 pandemic Severe infection severity significantly increased systemic effects the SARS-CoV-2 Vesicle volunteers was increased
[DOI] 10.3390/cells10020386 PMC 바로가기 [Article Type] Article

Impact of intravenous lidocaine on clinical outcomes of patients with ARDS during COVID-19 pandemia (LidoCovid): A structured summary of a study protocol for a randomised controlled trial

COVID-19 대유행 중 ARDS 환자의 임상 결과에 대한 정맥내 리도카인의 영향(LidoCovid): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-02-112022-09-10
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 24 hour 24 hours acute renal failure acute respiratory distress acute respiratory distress syndrome Admission adverse event adverse events age albumin All participant All participants Anti-inflammatory effects approved aPTT ARDS Atrial fibrillation Bacterial Berlin Beta Bicarbonate biological sample biological samples blinded Blinding blockers blood count bolus bronchospasm cardiac rhythm Cardiogenic shock Care care providers Child bearing clinical Clinical data Clinical outcome clinical study collected Commission comparator complete blood count Complication computer-generated Concentration conducted Consumption control group cough COVID-19 COVID-19 pneumonia Covid-19 subgroup CRP D-dimers delirium diagnostic Disease progression disorders dissemination distribution Distribution ratio dosage Effect element ethics committee evaluate the effect evaluated Evolution experimental group extubation ferritin fibrinogen FiO2 followed by following form France French Gas exchange HCG Hospitalized hypnotics ICU IL-6 Ileus Impact incidence include inclusion criteria Inflammation Inflammatory marker inflammatory markers intensive care intensive care unit interval intervention group intravenous Intubated investigator LDH Length lidocaine Local local anaesthetics Local anesthetics Lymphocytes moderate moderate to severe Modification molecular mechanisms of pharmacological action Mortality NaCl number objective Older opioids outcome Pandemia PaO2 PaO2/FiO2 ratio parallel group participant Patient patients with ARDS PCT Phase 3 Placebo placebo-controlled Platelets Pneumonia pneumopathy Pneumothorax Prevent Primary outcome protection Protective protocol QTc random randomisation randomised randomised controlled trial randomize Randomized Randomly receive Recovery time recruitment Registered Renal Dialysis renal failure report respiratory distress RT-PCR Sample size SARS-CoV2 infection secondary endpoint Secondary endpoints sedated Severe acute respiratory syndrome severe ARDS Shock Social Security Social security system sore throat status Stratification stroke Study protocol supplementary material surgical syndrome tetraplegia thromboembolic Thromboembolic event timepoint Toxicity Treatment Trial Trial registration triglycerides troponin two group two groups university vasopressors Ventilation ventilator ventilator-free day Ventilator-free days website women written Informed Consent
[DOI] 10.1186/s13063-021-05095-x PMC 바로가기 [Article Type] Letter

A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial

COVID19에 감염된 종양-혈액학적 환자에서 호흡 부전 진행을 예방하기 위한 바리시티닙의 효능을 평가하기 위한 I/II상 임상 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-02-052022-09-10
Journal: Trials [Category] MERS, 임상, 치료제,

[키워드] 1:1 AAK1 absence activator Acute respiratory failure Administered administration Adverse adverse events affected alkaline phosphatase All participants allergy Alpha alpha error angina pectoris Antibiotics appearance ARDS Arm assigned AST/ALT Baricitinib baseline beta error Bilirubin Blinding Blood Breastfeeding can be used candidate Candidates capture Cardiac arrhythmia carried change clearance clinical clinical condition clinical suspicion clinical trials Coagulation Cohort Common Terminology Criteria Comorbidity Complete completion Compliance congestive heart failure control arm Controlled trial corticoid Corticosteroids COVID19 creatinine creatinine clearance CRP D-dimer Day Deep venous thrombosis description Deterioration Dexamethasone dimer discharge discretion disease dissemination diverticulitis dose dropout rate Duration of therapy ECMO Efficacy electronic case report form element eligibility criteria Enrollment evaluate exclusion criteria expected experimental arm extracorporeal membrane oxygenation febrile neutropenia ferritin followed by form fraction Gas exchange greater HBV HCV hemodynamic instability High-flow nasal cannula HIV HIV infection ICU immobilization immunological impossibility incidence include indication Infection infection with SARS-CoV-2 Inflammatory response interfere interferon Interim interim analysis interleukin interleukin 6 interstitial pneumonia Intervention intestinal perforation Invasive mechanical ventilation investigational agent investigator jak inhibitors Jak-STAT Laboratory laboratory parameter Laboratory parameters LDH less limit limits management mechanical ventilation medical history Medicine meet Methylprednisolone Mild ARDS Mortality multi organ failure nasal nasal cannula need for oxygen neutropenia neutrophil Neutrophils Non-invasive number objective on mechanical ventilation oncological patients onset of symptom open open label oral medication organ dysfunction Organ failure outcome oxygen oxygen support PaFi participant Participants Participation pathogen Pathogens pathway Patient patients performance status performed phase Phase 1 Phase 2 Phase I phosphatase platform Pneumonia poor prognosis positive Prednisone pregnancy test pregnant prejudice Prevent progression Prophylaxis Protein protein kinase protocol Psychiatric psychiatric illness Pulmonary embolism radiological randomisation randomised randomised controlled trial randomization Randomized Randomized controlled trial receive receptor recruitment REDCap REDcap platform reduce reduced Remdesivir removal report reported required respiratory Respiratory failure Respiratory function respiratory insufficiency respiratory tract Sample size SARS-CoV-2 SARS-CoV2 SARS-CoV2 infection Secondary objectives Sepsis severe adverse event severe adverse events severe pneumonia severe respiratory failure Spain Spanish Standard of care STAT status study enrollment Study protocol supplemental oxygen requirement supplemental oxygen requirements supplementary material Support surgical surgical intervention Symptom symptomatic Tablet Therapies therapy thromboembolic disease thrombosis Tocilizumab total bilirubin Toxicity Transcription transducer Treatment treatment period Trial unstable angina use of corticosteroid Venous thrombosis Version viral endocytosis website Withdrawal worsening
[DOI] 10.1186/s13063-021-05072-4 PMC 바로가기 [Article Type] Letter

Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial

코로나바이러스 감염증(COVID-19) 감염이 확인된 병원에 입원한 환자의 레닌-안지오텐신-알도스테론 시스템 차단 관리(The McGill RAAS-COVID-19): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Study Protocol

Published on 2021-02-052022-09-10
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 48 hour 48 hours ACE inhibitor ACE2 Acute kidney injury Admission age aldosterone All participants Amendment Analysis Anticoagulants approach assigned baseline Biomarker Biomarkers blinded Blinding blockade blood pressure BNP C-reactive protein C-reactive protein (CRP calculated calibrated cardiovascular disease change Clinical improvement clinical trials collected comparator component Consent coronavirus disease COVID-19 COVID-19 diagnosis COVID-19 infection COVID-19 patient creatinine creatinine) CRP database death diagnosis of COVID-19 died discharge dissemination domains doubling Effect EGFR Ejection fraction element eligible Endpoint enrolment Estimated Ethnicity evaluate event exclusion criteria feasibility Follow-up followed by General Hospital greater groups Health Health Organization heart failure high blood pressure highest hospital ICU ICU admission immunopathology include Inclusion inclusion and exclusion criteria increase increase in Increases indicate Infection inhibitor inhibitors initial initiated intervention arm intravenous invasive ventilation list Lower lowest lymphocyte Lymphocyte count lymphocyte counts mathematical mathematical model McGill University mean rank mechanical ventilation medical history medication medications meet Montreal Mortality number objective Older open open label Ordinal Scale outcome outcomes participant Participants past medical history Patient patient cohort PCR performed Prevent primary end point primary endpoint Protein protocol provided RAAS RAAS inhibitor random number generator randomised randomised controlled trial randomization Randomized Randomized controlled trial recruitment reduced Registration Renin required Sample Sample size SARS- CoV2 secondary secondary endpoint sensitivity sensitivity analysis serum creatinine Sex short term stability statistical power calculations status stroke study participant Study protocol subsequent supplementary material System table team the patient the primary endpoint therapy transfer transferred Treatment Trial troponin Version Victoria ward website were excluded WHO withdrawn World Health Organization
[DOI] 10.1186/s13063-021-05080-4 PMC 바로가기 [Article Type] Study Protocol

Oxygen metabolism markers as predictors of mortality in severe COVID-19

심각한 COVID-19에서 사망의 예측인자로서의 산소 대사 마커

Observational Study

Published on 2021-02-012022-09-11
Journal: International Journal of Infectious Diseases [Category] MERS, SARS, 바이오마커, 임상,

[키워드] addition All participants Analysis ARDS arterial blood AUC Blood characteristic coronavirus disease Coronavirus disease 2019 COVID-19 Critically ill Critically ill patient critically ill patients cut-off cut-off point Deceased determinant Determinants of mortality had no healthy index individual marker medical record medical records metabolism Mortality oxygen Oxygen consumption Oxygen metabolism oxygen saturation oxygen) PaO partial pressure Participants Patient patients with COVID-19 predictor random number generator receiver operating characteristic respiratory Respiratory failure respiratory index Retrospective analysis selected severe coronavirus disease severe COVID-19 Significant significant differences survivor Survivors the strongest venous venous blood was determined with COVID-19
[DOI] 10.1016/j.ijid.2020.12.012 PMC 바로가기 [Article Type] Observational Study

Ruling out COVID-19 by chest CT at emergency admission when prevalence is low: the prospective, observational SCOUT study

유병률이 낮을 때 응급 입원 시 흉부 CT로 COVID-19 배제: 전향적 관찰 SCOUT 연구

Observational Study

Published on 2021-01-122022-09-01
Journal: Respiratory Research [Category] MERS, 임상, 진단,

[키워드] 95% CI 95% confidence interval Accuracy Admission All participant All participants Antibody test antibody tests calculated certainty Chest computed tomography Chest CT cohort study complement Computed tomography Contact COVID-19 diagnosis of COVID-19 diagnostic Diagnostic accuracy emergency department evaluate exclusion infected individuals Infection likelihood ratio low-dose male Negative predictive value nomogram outcome measure participant Patient polymerase chain polymerase chain reaction positive Predictive value predictive values presenting Prevalence prevalence of COVID-19 reference standard Referral referred to repeated Result Reverse transcriptase polymerase chain reaction reverse transcription reverse transcription polymerase chain reaction RT-PCR RT-PCR testing Sensitivity and specificity severe acute respiratory syndrome coronavirus 2 specificity Symptom theorem Trial registration Virus Disease were used with COVID-19
[DOI] 10.1186/s12931-020-01611-w PMC 바로가기 [Article Type] Observational Study

Cytokine profile and disease severity in patients with COVID-19

COVID-19 환자의 사이토카인 프로필 및 질병 중증도

Article

Published on 2021-01-012022-09-11
Journal: Cytokine [Category] 바이오마커,

[키워드] (enzyme-linked immunosorbent assay age All participants Analysis ANOVA both groups can be used collected Concentration conducted control group controls coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 patient COVID-19 patients cytokine Cytokine dysregulation cytokine level cytokine levels Cytokines disease severity dysregulation ELISA enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay evaluate healthy subject IFN-γ IL-17 IL-5 IL-8 IL-9 in both group infected with SARS-CoV-2 interferon interferon-γ interleukin involved mechanism Mild not differ one-way ANOVA participant Patient patients patients with COVID-19 Predictive proinflammatory responses serum Serum level serum levels serum sample serum samples severe group severity significant difference significant differences significantly significantly higher statistical analysis systemic tested TGF-β Th1 Th17 Treg was performed
[DOI] 10.1016/j.cyto.2020.155323 PMC 바로가기 [Article Type] Article